Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell?

Jasper Therapeutics, Inc. (NASDAQ:JSPR)’s share price traded down 7.3% on Monday . The company traded as low as $1.6050 and last traded at $1.64. 852,758 shares were traded during trading, a decline of 77% from the average session volume of 3,774,549 shares. The stock had previously closed at $1.77.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JSPR shares. BTIG Research reduced their price target on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. JMP Securities dropped their price target on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a research note on Monday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. Finally, Evercore ISI decreased their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, September 22nd. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Jasper Therapeutics has a consensus rating of “Hold” and an average target price of $20.29.

Jasper Therapeutics Trading Down 7.3%

The firm’s fifty day moving average is $2.01 and its 200 day moving average is $3.08. The company has a market cap of $45.89 million, a PE ratio of -0.28 and a beta of 3.06.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Monday, November 10th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.12). As a group, sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 EPS for the current fiscal year.

Insider Transactions at Jasper Therapeutics

In other news, CEO Ron Martell acquired 41,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were bought at an average price of $2.43 per share, for a total transaction of $99,630.00. Following the acquisition, the chief executive officer owned 74,118 shares of the company’s stock, valued at approximately $180,106.74. This trade represents a 123.80% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Thomas G. Wiggans bought 41,000 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were acquired at an average cost of $2.43 per share, with a total value of $99,630.00. Following the acquisition, the director directly owned 41,000 shares of the company’s stock, valued at approximately $99,630. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 143,000 shares of company stock valued at $347,490 in the last 90 days. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics during the first quarter worth approximately $46,000. Voleon Capital Management LP purchased a new stake in shares of Jasper Therapeutics in the third quarter valued at about $50,000. Marex Group plc purchased a new position in Jasper Therapeutics during the second quarter worth about $74,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at approximately $78,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at approximately $96,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.